Memorandum submitted by Dr Jean Monro
and Dr Peter Julu (HO 20)
SUMMARY OF
THE MAIN
POINTS BEING
MADE:
1. Homoeopathic dilutions resemble dilutions
of antigens made for low-dose immunotherapy.
2. Allergy is evinced by autonomic changes which
are physiologically demonstrable and measurable using the NeuroScope.
3. Low-dose immunotherapy can reverse dysautonomia.
This has been demonstrated before and after depictions of physiological
abnormalities.
4. Homoeopathic dilutions have been shown to
mirror the provocation and nullification of symptoms in different
dilutions which are evinced by low-dose immunotherapy dilutions.
5. The lymphocyte sensitivity test is described.
It shows sensitivity of lymphocyte membranes when exposed to agents
to which the patient is sensitive.
6. Low-dose immunotherapy can stabilise lymphocyte
membranes and abort abnormal cell membrane responses, hence controlling
symptoms of sensitivity.
7. The findings described have been published,
in the first instance, in a peer-reviewed publication and, subsequently
as presented to the Joint International Neurogastroenterology
and Motility Conference held in Chicago in August 2009.
8. Ongoing studies and observations corroborating
these findings have been undertaken and are in the process of
being collated.
9. There is clear, scientific evidence of the
mode of action of sensitivities, allergies through the autonomic
nervous system, which is the neural pathway of allergy and its
control through low-dose immunotherapy.
10. As low-dose immunotherapy and homoeopathy
are showing parallel effects, the findings in relation to low-dose
immunotherapy are relevant to homoeopathy.
1. In our attempt to investigate the physiological
evidence of low-dose immunotherapy, we have carried out several
studies which included dilution of antigens, up to homoeopathic
concentrations.[36]
These produced symptomatic responses at some dilutions and abrogations
of responses at others. Selected antigens which suited the individual
provoking no symptoms nor increased wheals when injected intradermally,
were then used for treating patients with migraine and food allergies.
Subsequently, with homoeopathic dilutions provided by Ainsworth
Homoeopathic Pharmacy, similar responses were observed of provocation
and nullification of symptoms.
2. Below are the graphic representations
of the response to homoeopathic concentrations.
SYMPTOMS TO MILK AT DIFFERENT DILUTIONS
SYMPTOMS TO MILK AT DIFFERENT DILUTIONS
3. The text in relation to these graphs
is as follows:
Fifteen patients were selected. Each of these
patients had been previously diagnosed as being allergic to wheat,
milk and egg, both by elimination diet followed by challenge which
induced symptoms or observable physiological changes, and by previous
skin testing using the provocation/neutralisation method, with
allopathic vaccines of 1:5 dilutions. The homoeopathic vaccines
were prepared by Ainsworth Homoeopathic Pharmacy in dilutions
of 1x, 6x, 10x, 30x.
Patients were exposed to each of these strengths
within their vials, and also injected intradermally, with a 0.05 ml
wheal being raised. Symptoms were noted and charted. Patients
then held the vial and symptoms were noted. Where symptoms occurred,
intermediary preparations of vaccines were obtained and charted.
Dilutions of antigens below Avogradro's number, viz homoeopathic
remedies, behaved in a manner similar to antigens injected sequentially,
as in the Miller provocation/neutralisation technique and homoeopathic
remedies have a similar pattern of provoking and neutralising
symptoms.
4. It was then necessary to further investigate
the physiological evidence of low-dose immunotherapy. This was,
therefore, designed in the experimental terms of "before
and after" evidence. This is an ongoing clinical evaluation,
but due to the urgency of this call for evidence, we want to share
with you our early results.
5. The first pilot study was carried out
and presented to the Joint International Neurogastroenterology
and Motility Conference in August 2009 this year, showing
very clear physiological responses to low-dose immunotherapy.
Autonomic dysfunction was demonstrated and this was corrected
by low-dose immunotherapy. We clearly showed that low-dose immunotherapy
manipulates the autonomic nervous system and this is the basis
for its mechanism of action. For example, we showed that low-dose
immunotherapy corrected dysfunction of the sympathetic nervous
system in both the splanchnic regions and skeletal muscles (see
illustration attached, as presented at the Joint International
Neurogastroenterology and Motility Conference 27-30 August
2009).
6. Further evidence of the mechanism of
action of the low-dose immunotherapy is biochemical/immunological.
The lymphocyte sensitivity assay is a test in which lymphocytes
are viewed by confocal microscopy on a slide in which the medium
is accessible to the addition of possible agents to which the
lymphocytes can react, if they are sensitive. In the medium is
a calcium probe which becomes fluorescent blue if the cell wall
is breached with calcium. When the person's cells are viewed initially,
the amount of calcium in the cell can be calculated by the density
of the fluorescent probe. Thereafter, different agents are added
to slides and the lymphocyte, if it is sensitive, will allow the
ingress of further calcium. This was undertaken before and after
the use of low-dose immunotherapy and shows a normalisation of
cell membranes as a result of low-dose immunotherapy.
7. These findings are clear scientific evidence
of the action of low-dose immunotherapy, and, since low-dose immunotherapy
with homoeopathic dilutions has been shown to work similarly,
giving parallel clinical results, we have no doubt that this is
the mechanism of action of homoeopathic agents.
8. We have, therefore, embarked on the clinical
evaluation of the physiological and chemical/immunological mechanisms
of homoeopathic dilutions of our antigens.
9. A memorandum was presented to the House
of Lords Science and Technology Select Committee on Allergy, Session
2006-07, which was chaired by Baroness Finlay of Llandaff. This
described the background of low-dose immunotherapy.
10. Further presentations were offered at
a seminar organised by Breakspear Hospital Trust at the House
of Commons when we were guests of Michael Penning MP Shadow Health
Minister. Information that was presented regarding allergy at
that meeting can be made available to the Science and Technology
Committee.
DECLARATION OF
INTERESTS:
Jean Monro—Director of Breakspear Medical
Group Ltd
Peter Julu—Inventor of NeuroScope
November 2009
36 Monro JA. Biological effects of neutralising vaccines:
the effects of weak electromagnetic fields and the concordance
between the two. Proceedings of the International Conference on
Electromagnetic Environments and Health in Buildings; 2002 May;
London. In: Clements-Croome D, editor. Electromagnetic environments
and health in buildings. London: Spon Press; 2004. p.267-80. Back
| 
